Kornimate/medical-research-clean huggingface dataset:
priming in repetitive transcranial magnetic stimulation in the treatment of obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: obsessive compulsive disorder results in high social impact, affecting quality of life and tending to a chronic course. a considerable proportion of patients, up tp 60%, remain with symptoms even thought treatment is administrated. therefore, new therapeutic interventions are highly necessary. in this context, repetitive transcranial magnetic stimulation has been used for several psychiatric conditions, including ocd treatment. moreover, many approaches of neuromodulation seem to reach a better result when used a priming stimulation. in an attemp to optimize particularities of the thecnique applied, this study aims to assess if a priming stimulation with rtms might impact in a better outcome when compared with rtms without previous stimulation.

this is a randomized, double-blind, sham-controlled clinical trial. neuropsychological tests and a sociodemographic and clinical questionnaire will be used to assess and characterize the subjects. participants captured by the laboratory of studies in aging and neuroscience at the federal university of paraíba will be divided into 02 groups, each with 16 patients, totaling 50 volunteers: active - participants who will receive real priming stimulation; sham - participants who will receive simulated priming stimulation. participants entered through the eligibility criteria will be randomly allocated in a simple way, at a rate of 1:1. in the active priming, the parameters are: frequency of 6 hz for 10 minutos, 80% do motor threshold (mt), 20 trains of 5 seconds, with intertrain interval of 25 seconds, a total f 600 stimulations. the group of innactive priming will have the same parameters, but without active atimulation. after this previous stimulation, all participants will receive the main stimulation: 10 sessions of rtms, each lasting around 20 minutes, for 5 days a week, during two consecutive weeks. the target area will be the supplementary motor area. primary outcome will be assessed by change in yale-brown obsessive compulsive scale scores. as secondary outcomes, it will be used ham-a for anxiety, ham-d for depression, cgi-s for global clinical impression and sf-36 for quality of life.

Eligibility criteria:
inclusion criteria: * being right-handed; * age between 18 and 60; * diagnose of ocd according to dsm-5; * score in ybocs between 16 and 23; * no change in dose prescription in the previous 3 months; * signature of informed consent term. exclusion criteria: * being pregnant; * having cognitive deficit; * diagnose of drug use disorder; * in current psychotherapy (or interrupted in less than 3 months); * diagnose of severe major depression; * risk of suicide; * patients with metallic implants in the brain; * epileptics.

Keywords: priming supplementary motor area obsessive-compulsive disorder transcranial magnetic stimulation
effectiveness of a pain education program on chronic neck pain patients

Conditions: Neck Pain

Summary: this project aims to study the effectiveness of a pain education program in the improvement of chronic pain and disability/impairment. assuming the definition established in the united states in 1975 on the fourth working group of the national conference on preventive medicine: "health education must be a process that informs, motivates and helps people to adopt and maintain practices and healthy lifestyles, environmental advocates changes necessary to facilitate these objectives and professional training and directs research towards the same objectives. " once the need of educating patients is stablished on subjects with diseases, it is necessary to encourage them to actively participate on the control of them and to achieve significant improvement of adherence

background and purpose: patient education over the knowledge of pain causes and perpetuating psicosocial factos, so as a gradual physical therapy intervention may success in modifying habits, and consequently emotional state and behaviour in order to maintain or recover subject's social participation being this program effective in pain diminution over chronic neck pain. main goal: to evaluate the effectiveness of a pain education program for patients with chronic neck pain, to decrease the intensity of pain in front of one physiotherapy program (tens and exercise) experimental group: will receive five group sessions of 60-120 minutes twice a week with a maximum of 10 participants. control group: five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (tens) on neck area an exercises. outcomes primary outcome * intensity of pain, measured by the visual analog scale: vas. the mean of the values wil be calculated described in the assessment, the mean of the last week was also compiled. * the degree of neck disability/impairment measured using the northwick park pain questionnaire (nppq)

Eligibility criteria:
inclusion criteria: * subjects over 18 years old * subjects diagnosed with chronic neck pain. exclusion criteria: * patients with acute and subacute neck pain. those presenting inflammatory, neurologic, rheumatic or heart disease or pacemakers. patients with severe osteoporosis, fractures, dislocations, vertebrobasilar insufficiency, infection, metastatic tumor, pre and post-surgical etiology recent (less than one year after the intervention). psychopathology patients diagnosed by their doctor. subjects who do not understand or speak the spanish language.
late toxicity in breast cancer patients treated with breast-conserving surgical procedures and radiotherapy using the simultaneous integrated boost technique

Conditions: Breast Cancer

Summary: in summary, breast conserving therapy (bct) is an effective, save and widely used treatment technique for early breast cancer. radiotherapy has shown to give better local control and survival benefit and is an integrated part of bct. the simultaneous integrated boost (sib) technique is a new treatment technique in breast irradiation. in this technique the whole breast is irradiated simultaneous with boosting the tumour bed, as part of bct. late radiation-induced toxicity has not been investigated in patients treated with radiotherapy using this technique. proposed study will study the late radiation-induced toxicity, describe patients-rated complaints, quality of life, survival and local control curves in patients treated for early breast cancer with breast-conserving surgery in combination with radiotherapy with the sib technique as compared to sequential radiotherapy treatment.


Eligibility criteria:
inclusion criteria: * who performance status 0-2. * invasive breast cancer or ductal carcinoma in situ (dcis). * stage i-iii breast cancer or dcis. * treated with curative radiotherapy of the breast (as part of breast conserving therapy) with simultaneous integrated boost technique, with or without irradiation of the regional (including internal mammary) lymph nodes. exclusion criteria: * previous thoracic radiotherapy. * previous history of malignancy, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin. * bilateral (synchrone) invasive breast cancer. * treatment prior to surgery (i.e. neoadjuvant chemotherapy, neoadjuvant hormonal therapy, pre-operative radiotherapy). * distant metastases at diagnosis (m1). * unsufficient knowledge of dutch language.

Keywords: late toxicity simultaneous integrated boost (sib) radiotherapy
effect of early enteral nutrition on serum acetylcholine level and inflammation in critically ill patients

Conditions: Critical Illness; Enteral Nutrition; Inflammation

Summary: early enteral nutrition(een) is an important treatment for critical ill patients and attenuate systemic inflammation, but the mechanisms are not clear. thus the investigator conducted this study to observe if een affects systemic inflammation though regulation of blood acetylcholine


Eligibility criteria:
inclusion criteria: * initiating enteral nutrition within the first 24-48h after intensive care unit (icu) admission * age more than 18 years * acute physiology and chronic health evaluation ii (apache ii) score \>8 exclusion criteria: * not expected to survive 24 hours * pregnancy * any terminal stage disease
low intensity resistance training with partial blood flow restriction for quadriceps strengthening

Conditions: Knee Osteoarthritis; Symptomatic Knee Osteoarthritis

Summary: the objective of the proposed research is to assess the efficacy of an eight-week, efficient and tolerable, low-intensity resistance-training program with concurrent application of partial blood flow restriction (pbfr) for improving quadriceps strength and volume in women with risk factors for incident symptomatic or progressive knee oa. this specific aim will be achieved through a randomized, controlled trial, comparing low intensity training with and without pbfr. there have been numerous reports of exercise interventions in people with knee osteoarthritis. however, this research is novel in that it will be the first to use a low intensity regimen that will minimize forces on the knee while still having the potential to lead to clinically meaningful strength gains in older adults with risk factors for incident symptomatic or progressive knee oa.


Eligibility criteria:
inclusion criteria: * female * age 45-60 * bmi less than 37 and greater than or equal to 25 kg/m2, or a history of a knee joint injury or surgery, or knee symptoms (pain, aching, or stiffness) on most of the last 30 days, or knee osteoarthritis exclusion criteria: * resistance training at any time in the last 3 months prior to study * 5° malalignment of a knee * bilateral knee replacement * lower limb amputation * lower limb surgery in the last 6 months that affects walking ability or ability to exercise * back, hip or knee problems that affect walking ability or ability to exercise * unable to walk without a cane or walker * unable to ascend at least 2 stairs (to enter our building) * inflammatory joint or muscle disease such as rheumatoid or psoriatic arthritis or polymyalgia rheumatica * multiple sclerosis * known neuropathy * self-report of diabetes * currently being treated for cancer or having untreated cancer * terminal illness (cannot be cured or adequately treated and there is a reasonable expectation of death in the near future) * peripheral vascular disease * history of myocardial infarction or stroke in the last year * deep venous thrombosis * chest pain during exercise or at rest * use of supplemental oxygen * inability to follow protocol (e.g. lack of ability to attend visits or understand instructions) * staff concern for subject health (such as history of dizziness/faintness or current restrictions on activity) * concurrent study participation (such as the most study) * planning to be away for more than one week during the study

Keywords: knee osteoarthritis isokinetic knee extensor strength quadriceps volume symptomatic knee osteoarthritis
house dust mite allergen reduction in bedding: purotex impregnated covers of bekaert textiles

Conditions: Allergic Rhinitis

Summary: product information: purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. study design: * placebo-controlled: the effect of the purotex impregnated mattress and pillow covers will be compared to untreated, classical bedding covers (placebo). * cross-over design: there will be 2 'treatment' arms. one arm (arm 1) in which the subjects will first use the purotex impregnated covers (set a=purotex) during 2 months (=period a) and, after a wash out period of 1 month, the untreated covers (set b=placebo) during 2 months (=period b). in the second arm (arm 2), the subjects will first use the untreated set (set a=placebo) and, after a wash out period the purotex impregnated covers (set b=purotex). * randomized: the subjects will be randomly assigned to one of the 2 treatment arms. * double blind: both the subjects and the investigators will not know to which treatment arm the subjects are assigned. study hypothesis: we want to investigate: * if there is a reduced concentration of hdm allergen in purotex covers compared to untreated covers in real life * if patients with allergic rhinitis to house dust mite use the purotex covers, they experience an improvement of their quality of life and sleep, and an improvement of their allergic symptoms and global discomfort


Eligibility criteria:
inclusion criteria: * subjects must be willing to give/sign informed consent * subjects (male or female) must be at least 18 years old and maximum 65 years old at screening * clinical history of allergic rhinitis for at least 1 year * positive skin prick test for d. pteronyssinus ± d. farinae * positive nasal provocation test with the house-dust-mite allergen * specific ige: unicap positive to d. pteronyssinus (d1) and d. farinae (d2) (\> 0.7u/ml) * vas score for global discomfort caused by nasal- or other allergic symptoms during the previous 4 weeks ≥ 5. * the concentration of der p1 in the dust collected from own bedding (mattress and pillow), measured by elisa is above the detection limit (≥ 0.488 ng/ml). exclusion criteria: * patients sensitized to animals should not be included if they are symptomatic upon exposure and regularly exposed to animals: positive spt to pets and pets at home * patients with an allergy to tree pollen (symptoms during the season + positive skin prick test) should not be included * subject pregnant or lactating * completed allergen specific immunotherapy (scit or slit) with hdm within the last 5 years * scit or slit during the study period * regular use of oral corticosteroids for exacerbations of asthma * daily use of oral corticosteroids * daily use of cyclosporine or other immunosuppressant drugs * regular use of antibiotics * history of anaphylactic reaction to an allergen * severe general diseases (especially cardiopulmonary disease with reduced lung capacity)
treatment of port wine stains using pulsed dye laser, erbium yag laser and topical sirolimus

Conditions: Port-Wine Stain

Summary: the purpose of this study is to improve the therapeutic outcome of laser therapy for port wine stains by using a combination treatment of the pulsed dye laser (pdl), erbium yag laser and topical sirolimus.

in the first treatment period all patients will receive a total of five treatments with two week intervals. every patient will receive the following four treatments (utilizing a template with separate squares of 1cm2): 1) pdl treatment followed by topical sirolimus application after er:yag laser ablation of the stratum corneum compared with 2) pdl treatment followed by topical sirolimus application without er:yag laser ablation of the stratum corneum, 3) pdl treatment only and 4) sirolimus application only. after the six months follow-up period, during the second treatment period, patients will receive an additional five treatments of the adjacent cosmetic unit of the treated part of the pws, employing the most successful of the four treatment modalities as evaluated after the first treatment period.

Eligibility criteria:
inclusion criteria: * subject has provided informed consent; * subject is ≥ 18 years of age at time of screening; * subject has an extra-facial homogenous port wine stain (pws); * the pws is large enough in size to fit one of the templates * subject has not received any laser treatment of the pws in the last 3 months (in the treatment area); * the pws has a minimal erythema grading score of 3 (on a 4 point scale) in the opinion of the investigator; * screening blood safety values are within normal parameters or regarded as not clinically significant in the opinion of the investigator. exclusion criteria: * pws with a nodular/hypertrophic component in the treatment area; * pws on cosmetically unacceptable locations in the opinion of the investigator; * for women: pregnant or breast feeding during the treatment period; * women of child-bearing potential, unless they are using adequate contraceptive measures * subject is known to have immune deficiency, or is immune compromised * known allergy to sirolimus or other constituents of the study medication; * incapacitated subjects; * any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
the development and effectiveness of heart failure self-health management application

Conditions: Heart Failure

Summary: aims: to develop a smartphone application and investigate its effectiveness on patients with heart failure after using the "heart failure self-health management application.".

abstract aims: to develop a smartphone application and investigate its effectiveness on patients with heart failure after using the "heart failure self-health management application.". design: the single-group pre- and post-test experimental design was adopted. methods: this study used convenience sampling and the one-group pretest and posttest design as the research methods and developed the "heart failure self-health management application" using the google cloud database and web app. the research period was from july 1 to december 31, 2019, a total of 36 patients diagnosed with heart failure during hospitalization completed the pretest and posttest. this app (1) provides text and video heart failure self-care knowledge content; (2) enables users to record and browse blood pressure, heart rate, and weight; and (3) provides the data from the dutch heart failure knowledge scale and technology acceptance model. keywords: heart failure; self-health management; application

Eligibility criteria:
inclusion criteria: * heart failure exclusion criteria: * health

Keywords: heart failure
use of aromatherapy in conjunction with physical/occupational therapy in an acute care setting

Conditions: Suffering, Physical; Nausea

Summary: use of inhaled essential oils to reduce the symptoms of pain or nausea, enabling a patient to have increase participation with pt or ot, thereby minimizing hospitalization-related risks and potentially reducing the length of stay in the hospital.

the study intervention consists of 3 essential oils: lavender, mandarin and peppermint administered on an inhalation patch affixed in the chest region of the participant gown. the inhalation patch consists of hydrogel cast onto polyester film, supported by non-woven polyester fabric, covered with a polyethylene film. the proprietary foil-backed lamination on the patch is used to provide an occlusive barrier that prevents any essential oil from being absorbed through the skin. the placebo will consist of a comparable sized felt patch with adhesive backing with no essential oil applied.

Eligibility criteria:
inclusion criteria: 1. inpatients of acute care setting at university health hospital 2. provision of a signed and dated informed consent form 3. english or spanish speaking 4. male or female, aged 18 years and older 5. willing to comply with all study procedures exclusion criteria: 1. respiratory disorders, e.g., asthma, chronic obstructive pulmonary disease (copd), chronic bronchitis, emphysema, lung cancer, cystic fibrosis, pneumonia, pleural effusion 2. cognitive impairment 3. unable to communicate 4. admitted to the closed access unit or to psychiatry 5. allergic to lavender, mandarin or peppermint oil 6. diseases that cause olfactory disorders such as: covid-19, benign growths or polyps, congestion from a cold, sinus infection or allergy flare-up 7. drugs that may cause loss of the ability to smell e.g., intranasal zinc products, decongestant nose sprays and certain oral drugs such as nifedipine and phenothiazines 8. pregnant women (self-reported) 9. prisoner

Keywords: acute care physical therapy occupational therapy aromatherapy
ranibizumab for branch retinal vein occlusion associated macular edema study (rabames)

Conditions: Macular Edema

Summary: the primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (brvo) treated with argon laser photocoagulation versus intravitreal ranibizumab (lucentis®) injection versus a combination of both.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and older with chronic (\> 3months, \< 18 months) macular edema secondary to branch retinal vein occlusion * patients who at baseline have a bscva in the study eye between 20/320 and equivalent to 20/40, using an etdrs chart measured at 4 meters * patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by fluorescein angiography: * evidence that the macular edema extends under the geometric center of the foveal avascular zone. * evidence that the edema is only secondary to brvo (no other relevant ocular diseases, e.g. uveitis). * patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by optical coherence tomography (oct 3): * evidence that central macular thickness is \> 225 μm. * ability of subject to understand character and individual consequences of clinical trial. * signed and dated informed consent of the subject must be available before start of any specific trial procedures. * for women with childbearing potential, adequate contraception (negative pregnancy test result, serum or urine at trial entry, after treatment and at end of study). * only one eye of a patient may be included to this trial. exclusion criteria: * patients who at baseline * have a relevant ocular disease which may be associated with increased intraocular vegf levels (namely uveitis, neovascular glaucoma, neovascular age-related macular degeneration, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, and others) * have a relevant systemic disease which may be associated with increased systemic vegf levels (namely all malignancies) * had previous treatment for macular edema (laser, triamcinolone, vitrectomy) * pregnancy and lactation. * history of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * participation in other clinical trials within the last 3 months. * medical or psychological condition that would not permit completion of the trial or signing of informed consent. * arterial hypertension refractory to medical treatment

Keywords: macular edema secondary to branch retinal vein occlusion